Last reviewed · How we verify
Bis-Choline Tetrathiomolybdate
Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain.
Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain. Used for Wilson's disease.
At a glance
| Generic name | Bis-Choline Tetrathiomolybdate |
|---|---|
| Also known as | ALXN1840 |
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Drug class | Chelating agent |
| Target | Copper |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
This mechanism is thought to be beneficial in treating conditions such as Wilson's disease, where excessive copper accumulation in the brain leads to neurodegeneration. By reducing copper levels, Bis-Choline Tetrathiomolybdate may help slow or halt disease progression.
Approved indications
- Wilson's disease
Common side effects
- Hemolysis
Key clinical trials
- Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 (PHASE2)
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease (PHASE3)
- Bioavailability Study of 2 Oral Formulations of ALXN1840 (PHASE1)
- Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants (PHASE1)
- Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. (PHASE1)
- A Study of the Cardiac Effects of ALXN1840 in Healthy Adults (PHASE1)
- Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults (PHASE1)
- A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bis-Choline Tetrathiomolybdate CI brief — competitive landscape report
- Bis-Choline Tetrathiomolybdate updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI